Research programme: gene regulation therapeutics - Sangamo Therapeutics/Takeda
Alternative Names: hFVIII; SB-FVIII; ZFN genome editing therapeutics - Sangamo/Takeda; ZFP therapeutics - Sangamo/TakedaLatest Information Update: 24 Nov 2023
At a glance
- Originator Sangamo BioSciences; Shire
- Developer Sangamo Therapeutics
- Class Gene therapies; Transcription factors; Zinc finger DNA binding proteins
- Mechanism of Action Blood coagulation factor modulators; DNA-binding protein modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Huntington's disease
- Discontinued Haemophilia A
Most Recent Events
- 24 Nov 2023 Preclinical trials in Huntington's disease in USA (Parenteral) (Sangamo Therapeutics pipeline; November 2023)
- 28 Feb 2023 gene regulation therapeutics is still in early research in Huntington's disease in USA
- 23 Feb 2023 Discontinued - Preclinical for Haemophilia A in USA (Parenteral) (Sangamo Therapeutics pipeline, February 2023)